Myeloma is a type of cancer that affects plasma cells. It may show adverse effects on the skull, spine, pelvis, and ribs. Recently research has been published in the journal “The Lancet Oncology” that a drug is available for myeloma. A clinical trial was conducted at Newcastle University in Britain in which patients with myeloma were treated with lenalidomide. Myeloma is a serious type of bone marrow cancer which has been successfully treated by using lenalidomide.
Professor Graham Jackson from Northern Institute for Cancer Research says that after the first therapy by lenalidomide, the patient can stay without therapy longer and this no-therapy time increases with each drug administration phase.
Till now chemotherapy and Stem-cell transplant were used for the treatment of myeloma. But after the discovery of lenalidomide, tension has been released as it could effectively cure plasma cell cancer. It can help to save the lives of those with myeloma. Especially its no less than a miracle for children and younger patients. A bone marrow transplant is really difficult and lenalidomide has solved the problem greatly. Lenalidomide should be given to patients followed by stem cell transplantation.
To compare the effectiveness of lenalidomide with respect to age 1,137 patients were assigned to lenalidomide maintenance therapy and 834 to observation after the completion of their initial treatments. Lenalidomide reduces the spread of cancer up to 50% regardless of the age of patients. But it can prolong average remission time more in case of younger patients. It’s two years for younger patients compared to elder patients. The old only have one year.